Industry Overview - The 2025-2026 flu season in the United States is intensifying, primarily driven by a mutated strain of influenza A, leading to concerns about a challenging winter ahead [1] - As of late December 2025, the CDC estimates indicate that flu has caused at least 4.6 million illnesses, 49,000 hospitalizations, and 1,900 deaths nationwide [1][2] - Flu activity is rising sharply, with outpatient visits for influenza-like illness significantly above baseline levels in many states [2] Vaccination and Public Health - Vaccination rates are lagging, with over 47 million doses administered, down approximately 3 million from the previous year, increasing vulnerability among the population [2] - The World Health Organization reports a global increase in influenza activity since October 2025, with influenza A viruses being the most prevalent [3] Company Spotlight: Polyrizon Ltd. - Polyrizon Ltd. is an Israeli biotech company developing innovative medical device hydrogels, specifically the PL-16 Viral Blocker, a non-pharmaceutical hydrogel nasal spray [4][8] - The PL-16 product creates a temporary physical barrier on the nasal mucosa, potentially capturing and containing respiratory viruses before they can infect cells, showing over 90% protection in preclinical studies [5][6] - On December 19, 2025, Polyrizon submitted a Pre-Request for Designation to the FDA for PL-16, aiming for potential over-the-counter status to reduce exposure to respiratory viruses [6] Market Potential and Innovation - The PL-16 product is designed to complement existing vaccines, masks, and hygiene practices, providing an additional layer of defense during high-activity seasons [6][7] - Experts emphasize the importance of layered protection, suggesting that innovations like Polyrizon's PL-16 could serve as a drug-free tool for both vaccinated and unvaccinated individuals [7]
As Flu Surge Continues, Polyrizon's Nasal Spray Emerges as Potential Extra Shield Solution for Both Vaccinated and Unvaccinated